701 VETERANS CIRCLE, WARMINSTER, PA
2026 Annual Meeting Approves 2026 Omnibus Share and Incentive Plan
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
Financial Results, Press Release
News
Offers Admissible Expert Opinions to Support Its Enablement Defense
Claim Violated Patent Law During Operation Warp Speed
European Patent Revocation for Arbutus Biopharma Corporation's EP 254 Patent
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Notice of Exempt Offering of Securities
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload